So that is why we were coming up, Senator Grassley and I, with a way to sort of even the playing field.
it is entirely proper to put the burden on the drug companies to demonstrate that actually these have a pro-competitive,...
It is the pay-for-delay settlement that we have concerns about, Senator Grassley and I, Senator Vitter and Senator Frank...
It seems to me the evidence suggests that just putting it back to rule of reason should have--should do the trick based ...
In fact, after the Supreme Court ruling, an industry analyst said in a CNBC interview that the court created a 'holy mes...
Hatch-Waxman is supposed to be about--at least paragraph 4 certifications--challenging invalid or not infringed patents.
We are also a strong supporter of another bipartisan bill, Senate bill 504, the Fair and Immediate Release of Generics A...
allows operating companies to exploit the lack of transparency in patent ownership to win a tactical advantage that coul...
Let's be very clear about what these deals are all about.
this bill that Senator Grassley and I have that has bipartisan support would not affect the vast majority of the drug se...
I think they assume that because for a number of years they were settled without pay for delay.
American consumers and American taxpayers lose out on lower-cost generic drugs to the tune of billions of dollars each y...
I just want to again thank you for your work.
Thank you very much.
To me, when you look at the numbers and the change since those Circuit Court decisions, this is more than just about som...
We urge Congress to take action on Senate bill 214, the Preserve Access to Affordable Generics Act.
I think that there would be benefits of billions of dollars from outlawing these reverse payment settlements.
Pay-for-delay settlements are the most egregious form of antitrust violation in my mind.
